The Stomach pp 234-248 | Cite as

Therapeutic Strategy in Gastro-oesophageal Reflux Disease

  • J. P. Galmiche
  • S. Bruley des Varannes
  • C. Scarpignato
Conference paper


Gastro-oesophageal reflux disease (GORD) encompasses a wide spectrum of disorders in which gastric refluxate causes symptoms and/or damage to the oesophageal mucosa (Fig. 1). It is a very common disorder, epidemiological surveys in Europe and USA having shown that 5%–15% of the general population suffer from frequent heartburn or regurgitation [1, 2]. Most subjects, however, have mild, intermittent symptoms. They do not seek medical help or are managed by primary care physicians. At the other end of the spectrum of the disease are patients with long-standing recurrent disease, persistent symptoms, severe esophagitis lesions and complications such as strictures, bleeding, columnar-lined (Barrett’s) esophagus or extra-esophageal complications (e.g. asthma, acid laryngitis or non-cardiac chest pain).


Proton Pump Inhibitor Reflux Disease Gastroesophageal Reflux Disease Reflux Esophagitis Oesophageal Reflux Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Heading RC (1989) Epidemiology of oesophageal reflux disease. Scand J Gastroenterol 24 (suppl 168): 33–37Google Scholar
  2. 2.
    Bruley des Varannes S, Galmiche JP, Bernades P, Bader JP (1988) Douleurs épigastriques et régurgitations: épidémiologie descriptive dans un échantillon représentatif de la population française. Gastroenterol Clin Biol 12: 721–728Google Scholar
  3. 3.
    Janssens J, Galmiche JP (1990) Pathophysiology of gastro-oesophageal reflux. In: Vantrappen G, Mainguet P (eds) Peptic oesophagitis. Diagnosis and treatment. Excerpta Medica, Amsterdam, pp 9–18Google Scholar
  4. 4.
    Hirschowitz BI (1991) A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 95: 37–43Google Scholar
  5. 5.
    Gotley DC, Morgan AP, Ball D, Owen RW, Cooper MJ (1991) Composition of gastro- oesophageal refluxate. Gut 32: 1093–1099PubMedCrossRefGoogle Scholar
  6. 6.
    Zaninotto G, Di Mario F, Costantini M et al. (1992) Oesophagitis and pH of refluxate: an experimental and clinical study. Br J Surg 79: 161–164PubMedCrossRefGoogle Scholar
  7. 7.
    Heading RC, Eaves NR (1992) Aims of treatment in gastroesophageal reflux disease. In: Scarpignato C (ed) Advances in drug therapy of gastroesophageal reflux disease. Frontiers of gastrointestinal research, vol 20. Karger, Basel, pp 1–10Google Scholar
  8. 8.
    Kitchin LI, Castell DO (1991) Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 151: 448–454PubMedCrossRefGoogle Scholar
  9. 9.
    Kahrilas PJ (1992) Cigarette smoking and gastroesophageal reflux disease. Dig Dis 10: 61–71PubMedCrossRefGoogle Scholar
  10. 10.
    Sontag S J, O’Connell S, Khandelwal S et al. (1990) Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 99: 613–620PubMedGoogle Scholar
  11. 11.
    Bell NJV, Hunt RH (1992) Role of gastric acid suppression in the treatment of gastro- oesophageal reflux disease. Gut 33: 118–124PubMedCrossRefGoogle Scholar
  12. 12.
    Scarpignato C (1992) Advances in drug therapy of gastroesophageal reflux disease. Frontiers of gastrointestinal research, vol 20. Karger BaselGoogle Scholar
  13. 13.
    Koelz HR (1989) Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs. An analysis of randomized clinical trials. Scand J Gastroenterol 24 (suppl. 156): 25–36CrossRefGoogle Scholar
  14. 14.
    Scarpignato C, Galmiche JP (1988) Mucosal coating agents: pharmacology and clinical use. In Bianchi-Porro G (ed) Topics in digestive disease. Raven, New York, pp 73–133Google Scholar
  15. 15.
    Thomson ABR (1992) Medical treatment of gastroesophageal reflux disease: options and priorities. Hepato-Gastroenterol 39 (suppl 1): 14–23Google Scholar
  16. 16.
    Scarpignato C, Galmiche JP (1992) Antacids and alginates in the treatment of gastroesophageal reflux disease: how do they work and how much are they clinically useful? In: Scarpignato C (ed) advances in drug therapy of gastroesophageal reflux disease. Frontiers of gastrointestinal Research. Basel, Karger, pp 153–181Google Scholar
  17. 17.
    Behar J, Sheahan DG, Biancani P, Spiro HM, Storer EH (1975) Medical and surgical management of reflux esophagitis. A 38-month report on a prospective clinical trial. N Engl J Med 293: 263–268PubMedCrossRefGoogle Scholar
  18. 18.
    Vermeijden JR, Tytgat GNJ, Schotborgh RH et al. (1992) Combination therapy of sucralfate and ranitidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis. Scand J Gastroenterol 27: 81–84PubMedCrossRefGoogle Scholar
  19. 19.
    McCallum RW, Prakash C, Campoli-Richards DM, Goa KL (1988) Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 36: 652–681PubMedCrossRefGoogle Scholar
  20. 20.
    Ceccatelli P, Janssens J, Vantrappen G, Cucchiara S (1988) Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 29: 631–635PubMedCrossRefGoogle Scholar
  21. 21.
    Galmiche JP, Fraitag B, Filoche B et al. (1990) Double-blind comparison of cisapride and Cimetidine in treatment of reflux esophagitis. Dig Dis Sci 35: 649–655PubMedCrossRefGoogle Scholar
  22. 22.
    Rode H, Stunden RJ, Mikllar AJW, Cywes S (1987) Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopram- ide. J Pediat Surg 22: 931–934PubMedCrossRefGoogle Scholar
  23. 23.
    Janisch HD, Hutteman W, Bouzo MH (1988) Cisapride versus ranitidine in the treatment of reflux esophagitis. Hepato-Gastroenterol 35: 125–127Google Scholar
  24. 24.
    Galmiche JP, Brandstatter G, Evreux M et al. (1988) Combined therapy with cisapride and Cimetidine in severe reflux esophagitis. Gut 29: 675–681PubMedCrossRefGoogle Scholar
  25. 25.
    Wienbeck M (1986) Therapeutic effect of cisapride added on to ranitidine in patients with reflux esophagitis. Dig Dis Sci 31: 275AGoogle Scholar
  26. 26.
    Toussaint J, Gossuin A, Deruyttere M, Hublé F, Devis G (1991) Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 32: 1280–1285PubMedCrossRefGoogle Scholar
  27. 27.
    Tytgat GNJ, Hansen O J A, Carling L et al. (1992) Effect of cisapride on relapse of reflux oesophagitis healed with an antisecretory drug. Scand J Gastroenterol 27: 175–183PubMedCrossRefGoogle Scholar
  28. 28.
    Sato TL, Wu WC, Castell DO (1992) Randomized, double-blind, placebo-controlled crossover trial of pirenzepine in patients with gastroesophageal reflux. Dig Dis Sci 37: 297–302PubMedCrossRefGoogle Scholar
  29. 29.
    Koelz HR, Birchler R, Bretholz A et al. (1986) Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 91: 1198–1205PubMedGoogle Scholar
  30. 30.
    Johnson NJ, Laws S, Mills JG, Wood JR (1991) Effect of three ranitidine dosage regimens in the treatment of reflux oesophagitis: results of a multicentre trial. Eur J Gastroenterol Hepatol 3: 769–774Google Scholar
  31. 31.
    Quick RPF, Cooper MJ, Gleeson M et al. (1990) A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis. Aliment Pharmacol Therap 4: 201–211CrossRefGoogle Scholar
  32. 32.
    Wesdorp ICE (1992) Famotidine in gastroesophageal reflux disease (GERD). Hepato-Gastroenterol 39 (suppl 1): 24–26Google Scholar
  33. 33.
    Orr WC, Robinson MG, Humphries TJ, Antonello J, Caglioola A (1988) Dose-response effect of famotidine on patterns of gastro-oesophageal reflux. Aliment Pharmacol Therap 2: 229–235CrossRefGoogle Scholar
  34. 34.
    Johansson KE, Tibbling L (1986) Gastric secretion and reflux pattern in reflux oesophagitis before and during ranitidine treatment. Scand J Gastroenterol, 21: 487–492PubMedCrossRefGoogle Scholar
  35. 35.
    Robertson DAF, Aldersley MA, Shepherd H, Lloyd RS, Smith CL (1987) H2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response? Gut 28: 946–949PubMedCrossRefGoogle Scholar
  36. 36.
    Collen J, Lewis JH, Benjamin SB (1990) Gastric acid hypersecretion in refractory gastroeso-phageal reflux disease. Gastroenterology 98: 654–661PubMedGoogle Scholar
  37. 37.
    Collen MJ, Johnson DA (1992) Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett’s esophagus. Dig Dis Sci 37: 570–576PubMedCrossRefGoogle Scholar
  38. 38.
    Jansen JBMJ, Baak LC, Lamers CBHW (1988) Effect of increasing doses of ranitidine on exposure of the esophagus to gastric acid in patients with reflux esophagitis. Scand J Gastroenterol 23 (suppl. 154): 2–5CrossRefGoogle Scholar
  39. 39.
    Castell DO (1991) Rationale for high-dose H2-receptor blockade in the treatment of gastro- oesophageal reflux disease. Aliment Pharmacol Therap, 5 (suppl 1): 59–67Google Scholar
  40. 40.
    Johnson NJ, Boyd EJS, Mills JG, Wood JR (1989) Acute treatment of reflux esophagitis: a multicentre trial to compare 150 mg ranitidine b. d with 300 mg ranitidine q. d. s. Aliment Pharmacol Therap 3: 259–266CrossRefGoogle Scholar
  41. 41.
    Tytgat GNJ, Nicolai JJ, Reman FC (1990) Efficacy of different doses of Cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 99: 629–634PubMedGoogle Scholar
  42. 42.
    Smith JL, Opekun AR, Larkai E, Graham DY (1989) Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 96: 683–689PubMedGoogle Scholar
  43. 43.
    Maton PN (1991) Drug therapy: omeprazole. N Engl J Med 324: 965 - 975PubMedCrossRefGoogle Scholar
  44. 44.
    Hetzel DJ, Dent J, Reed WD et al. (1988) Healing and relapse of severe peptic esophagitis after treatment with omeprazole: a dose response study. Gastroenterology 95: 903–912PubMedGoogle Scholar
  45. 45.
    Sontag S J, Hirschowitz BI, Holt S et al. (1992) Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. multicenter study. Gastroenterology 102: 109–118PubMedGoogle Scholar
  46. 46.
    Koop H, Arnold R (1991) Long-term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci 36: 552–557PubMedCrossRefGoogle Scholar
  47. 47.
    Klinkenberg-Knol EC (1992) The role of omeprazole in healing and prevention of reflux disease. Hepato-Gastroenterol 39 (Suppl 1): 27–30Google Scholar
  48. 48.
    Stein HJ, Demeester TR (1992) Who benefits from antireflux surgery? World J Surg 16: 313–319PubMedCrossRefGoogle Scholar
  49. 49.
    Spechler S J et al. (1992) Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med 326: 786–792PubMedCrossRefGoogle Scholar
  50. 50.
    Cuschieri A, Shimi S, Nathanson LK (1992) Laparoscopic reduction, crural repair, and fundoplication of large hiatal hernia. Am J Surg 163: 425–430PubMedCrossRefGoogle Scholar
  51. 51.
    Nathanson LK, Shimi S, Cuschieri A (1991) Laparoscopic ligamentum teres (round ligament) cardiopexy. Br J Surg 78: 947–951PubMedCrossRefGoogle Scholar
  52. 52.
    Lieberman DA (1987) Medical therapy for chronic reflux esophagitis. Long-term follow-up. Arch Intern Med 147: 1717–1720PubMedCrossRefGoogle Scholar
  53. 53.
    Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Muller-Lissner SA (1992) Three year follow up of patients with gastro-oesophageal reflux disease. Gut 33: 1016–1019PubMedCrossRefGoogle Scholar
  54. 54.
    Olden K, Triadafilopoulos G (1991) Failure of initial 24-hour esophageal pH monitoring to predict refractoriness and intractability in reflux esophagitis. Am J Gastroenterol 86: 1142–1146PubMedGoogle Scholar
  55. 55.
    Fraser R, Verdu E, Armstrong D, Blum A (1992) Gastroesophageal reflux disease, pH monitoring, and treatment. Current Opinion Gastroenterol 8: 562–572CrossRefGoogle Scholar
  56. 56.
    Klauser AG, Shindlbeck NE, Muller-Lissner SA (1990) Symptoms in gastro-oesophageal reflux disease. Lancet 335: 205–208PubMedCrossRefGoogle Scholar
  57. 57.
    Bigard MA, Colin R, Galmiche JP, Rampai P, De Meynard C (1990) Evolution des symptômes de reflux gastro-œsophagien (RGO) après 2 semaines de traitement par alginate-antiacide. Facteurs prédictifs et données endoscopiques chez les non-répondeurs. Gastroenterol Clin Biol 14: A110 (abstr.)Google Scholar
  58. 58.
    Bennett JR (1992) A practical approach to patient management. First united European Congress, Athens, 28 Sept 1992Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • J. P. Galmiche
  • S. Bruley des Varannes
  • C. Scarpignato

There are no affiliations available

Personalised recommendations